Jagsonpal Pharmaceuticals Limited

NSE JAGSNPHARM.NS

Jagsonpal Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2024: 15.50%

Jagsonpal Pharmaceuticals Limited EBITDA Margin is 15.50% for the year ending March 31, 2024, a 0.80% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Jagsonpal Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2023 was 15.38%, a 22.18% change year over year.
Jagsonpal Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2022 was 12.58%, a 0.73% change year over year.
Jagsonpal Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2021 was 12.49%, a 79.14% change year over year.
Jagsonpal Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2020 was 6.97%, a 8.09% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: JAGSNPHARM.NS

Jagsonpal Pharmaceuticals Limited

CEO	Mr. Manish Gupta
IPO Date	July 1, 2002
Location	India
Headquarters	T-210 J, Shahpur Jat
Employees	1,025
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Jagsonpal Pharmaceuticals Limited develops and manufactures bulk drugs and pharmaceutical formulations in the areas of women health, pain and analgesics, and general medicine. It offers general medicines, such as allergy management, immunity and cell protection, gut and mind management, anti-infectives, and dentist and ENT range products; and women's healthcare products, including pregnancy care, and dysfunctional uterine bleeding complications and management products. The company also provides pain and analgesics products in the areas of pain management, and bone and joint care. It offers drugs in the form of tablets, capsules, and syrups. The company was founded in 1964 and is based in New Delhi, India. Jagsonpal Pharmaceuticals Limited is a subsidiary of Aresko Progressive Private Limited.

Key trends

Past 5 years